SPOTLIGHT -
Dr. Wei on Trial of Venetoclax Plus Chemotherapy in AML
Andrew Wei, MBBS, PhD, clinical hematologist, head of Leukemia Research Group, Alfred Hospital, discusses venetoclax (Venclexta) plus chemotherapy in advanced myeloid leukemia (AML).
Read More
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL